jsmc-10101

STATUS OF CIRCULATING SERUM TRYPTASE IN HEALTHY OBESE AND COMORBIDLY OBESE CONDITIONS

Tebeen Jamal Nadir a, Zhian Salah Ramzi b, Saman Hussein Noori a, Ban Mousa Rashid c,Taha Othman Mahwi d and Beston Faiek Nore a,e

a Department of Biochemsitry, College of Medicine, University of Sulaimani.

b Department of Family and Community Medicine, College of Medicine, University of Sulaimani.

c Department of Biochemsitry College of Pharmacy, University of Sulaimani.

d Department of Medicine, College of Medicine, University of Sulaimani.

e Dept. of Health, Kurdistan Institution for Strategic Studies and Scientific Research, Sulaimani, Kurdistan Region, Iraq.

Submitted: 3/9/2016; Accepted: 12/12/2016; Published: 1/6/2017

DOI Link: https://doi.org/10.17656/jsmc.10101

ABSTRACT

Background

Serum Tryptase is one of most abundant protease secreted by mast cells and it account as indirect measure for a number of human abnormalities, such as mastocytosis, systemic anaphylaxis, obesity, allergy, asthma and various forms of cancer.

Objectives

In this study we focused on obese individuals and we investigated the relationships between total Serum Tryptase with age, gender, classes of obesity with/or without type 2 diabetes mellitus or dyslipidemia.

Methods

Estimation of serum tryptase, body mass index, lipid profile, and serum glucose were performed in population of 250 participants aged 12-80 years.

Results

Serum tryptase significantly increased with body mass index, with higher level of serum tryptase found among diabetic obese than healthy obese individuals. There was significantly increase serum tryptase with age, but no correlation was found between serum tryptase and gender, hemoglobin A1c, and fasting blood glucose.

Conclusion

Level of serum tryptase increases with age, being much more pronounced in adults older than > 16 years old than individuals < 16 years old regardless of their body mass index. Serum tryptase is significantly higher in serum’s of all obese participants compared to the healthy participants, regardless of the obesity-related complications; while the obesity related type 2 diabetes mellitus patients shows a significantly highest level of serum tryptase compared to all other groups.

KEYWORDS

Serum Tryptase, obesity, Type 2 diabetes mellitus, Dyslipidemia, Body mass index.

References

1. Schwartz LB, Min HK, Ren S, Xia HZ, Hu J, Zhao W, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. Journal of immunology (Baltimore, Md : 1950). 2003;170(11):5667-73.

2. Vitte J. Human mast cell tryptase in biology and medicine. Molecular immunology. 2014.

3. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunology and allergy clinics of North America. 2006;26(3):451-63.

4. Lan RS, Stewart GA, Henry PJ. Role of protease-activated receptors in airway function: a target for therapeutic intervention? Pharmacology & therapeutics. 2002;95(3):239-57.

5. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. The Journal of allergy and clinical immunology. 2009;123(3):680-6.

6. Fenger RV, Linneberg A, Vidal C, Vizcaino L, Husemoen LL, Aadahl M, et al. Determinants of serum tryptase in a general population: the relationship of serum tryptase to obesity and asthma. International archives of allergy and immunology. 2012;157(2):151-8.

7. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101(12):4660-6.

8. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. European journal of clinical investigation. 2009;39(10):914-23.

9. Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nature medicine. 2009;15(8):940-5.

10. Gonzalez-Quintela A, Vizcaino L, Gude F, Rey J, Meijide L, Fernandez-Merino C, et al. Factors influencing serum total tryptase concentrations in a general adult population. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2010;48(5):701-6.

11. Divoux A, Moutel S, Poitou C, Lacasa D, Veyrie N, Aissat A, et al. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. The Journal of clinical endocrinology and metabolism. 2012;97(9):E1677-85.

12. Goldman L, Schafer AI. GOLDMAN-CECIL MEDICINE. 2015; 25th Edition, Vol. 1-2: pp. 3024. Elsevier Saunders, Philadelphia, USA.

13. Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochimica et biophysica acta. 2012;1822(1):14-20.

14. Shi MA, Shi GP. Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans. Frontiers in immunology. 2012;3:7.

15. Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, Willett WC, Rimm EB. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. American journal of epidemiology. 2004;159(12):1150-9.

16. Bianco A, Pomara F, Raccuglia M, Bellafiore M, Battaglia G, Filingeri D, et al. The relationship between type 2 diabetes family history, body composition and blood basal glycemia in sedentary people. Acta diabetologica. 2014;51(1):79-84.

17. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of internal medicine. 1995;122(7):481-6.

18. Moreno M, Puig J, Serrano M, Moreno-Navarrete JM, Ortega F, Ricart W, et al. Circulating tryptase as a marker for subclinical atherosclerosis in obese subjects. PloS one. 2014;9(5):e97014.

19. Gormsen LC, Nellemann B, Sorensen LP, Jensen MD, Christiansen JS, Nielsen S. Impact of body composition on very-low-density lipoprotein-triglycerides kinetics. American journal of physiology Endocrinology and metabolism. 2009;296(1):E165-73.

20. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nature medicine. 2007;13(6):719-24.

21. Heikkila HM, Trosien J, Metso J, Jauhiainen M, Pentikainen MO, Kovanen PT, et al. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. Journal of cellular biochemistry. 2010;109(3):615-23.

22. Lee M, Sommerhoff CP, von Eckardstein A, Zettl F, Fritz H, Kovanen PT. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arteriosclerosis, thrombosis, and vascular biology. 2002;22(12):2086-91.

Full Text

This work is licensed under a Creative Commons Attribution 4.0 International License.